Lung cancer patients on drug from China’s Akeso lived longer
Patients on ivonescimab lived longer by four months compared with those on immunotherapy.
Patients on ivonescimab lived longer by four months compared with those on immunotherapy.
Ranked reports inside the event cluster. Open any publisher link to read the original coverage.
Patients on ivonescimab lived longer by four months compared with those on immunotherapy.
Nearby clusters pulled from title, summary, and keyword similarity in PostgreSQL.
Erleada reduced the risk of the cancer spreading or death by 20 per cent. Grouped from 2 articles across 2 sources.
Those infected can get better and officials stress that people should seek medical help if they have symptoms. Grouped from 3 articles across 3 sources.
Daraxonrasib reduced the overall risk of death by 60 per cent compared with chemotherapy.
As the conflict destroys local production, Sudanese patients are forced to rely on expensive, smuggled medicines.
Experts hail daraxonrasib as ‘gamechanger’ for patients with advanced pancreatic cancer A daily pill can double survival time in patients with the world’s deadliest cancer, according to the results of a clinical trial…
An Iranian woman who now lives in the U.S. spoke with CBS News as the war with Iran entered its fourth month.